← Leaderboards
Mervyn Dodson Michael
Thermalin, Inc.
$3,270,508
Attributed
$3,270,508
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.6M · FY2019–21$2M$1.5M$1M$500K$0
'19
'20
'21
Funding mix
By agency
NIH$3,270,508 · 2
By mechanism
R44$2,994,231 · 1
R43$276,277 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pre-Clinical”
- Leonard Freedman · Leidos Biomedical Research, Inc.$264,541,531
- Lynn Briscoe · Leidos Biomedical Research, Inc.$110,540,429
- Ted Ross · University Of Georgia$68,763,143
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$57,713,529
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Research focus
Pre-ClinicalInsulin-Dependent Diabetes MellitusFormulationPostage StampsPumpInsulin Infusion SystemsDiabetes MellitusElementsInsulinNon-Insulin-Dependent Diabetes MellitusProductionPrototypeTechnologyAdherenceDesignDevicesAnalogDoseFundingInnovationBaseAfrican AmericanClinical ToxicologyAppalachian Region
Grant awards (3)
Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U500$1,570,780
R44 · FY2021 · DK · contact PI
Disrupting Insulin Delivery with a Novel, Stabilized Insulin that is Ultra-rapid at U100 or U500$1,423,451
R44 · FY2020 · DK · contact PI
StampPump: Proof of Principle for a Disruptive Insulin Delivery Technology$276,277
R43 · FY2019 · DK · contact PI